Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study
Authors' conclusion
Patients with EBV-positive rHLH are more likely to experience relapse or refractoriness.
Study context
- Population
- Patients with haemophagocytic lymphohistiocytosis (HLH) with underlying rheumatic diseases (rHLH)
- Participants
- 137 patients
- Exposure
- Epstein-Barr virus (EBV)-positive vs EBV-negative rHLH
- EBV-positiven = 21
- EBV-negativen = 116reference
- Outcome
- Survival time
Methodological detailssingle-centre, propensity score matching
- Single-centre
- Propensity score matching
Main finding
As reported in the abstract
- EBV-negative vs EBV-positive: P = 0.012
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Survival by EBV-infected lymphocyte subsetNK and/or T lymphocytes vs Other cell types · Kaplan-Meier analysis | P < 0.01 |
- Survival by EBV-infected lymphocyte subset: significant decrease in survival with NK and/or T lymphocytes
Relapsed or refractory rHLH
- EBV-positive patients more likely to have relapsed or refractory rHLH
Original publication
Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study. Clin Exp Rheumatol. Published 7 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →